Tarsus Pharmaceuticals (TARS) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 25, 2026, to be held virtually for stockholders of record as of April 27, 2026.

• Proxy materials, including the notice, proxy statement, and annual report, are available online, with paper copies available upon request.

Voting matters and shareholder proposals

• Election of four Class III directors to serve until the 2029 annual meeting or until successors are appointed.

• Advisory vote on named executive officer compensation (say-on-pay) to be held on a non-binding basis.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Provision to conduct any other business properly brought before the meeting or adjournment.

Board of directors and corporate governance

• Board recommends voting FOR all three main proposals, including director elections, executive compensation, and auditor ratification.

• Nominees for Class III directors are Wendy Yarno, Andrew Goldberg, Scott Morrison, and David E.I. Pyott.